Abstract
Highly active antiretroviral treatment (HAART), i.e. the combination of three or more drugs against human immunodeficiency virus type 1 (HIV-1), has greatly improved the clinical outcome of HIV-1-infected individuals. However, HAART is unable to reconstitute HIV-specific immunity and eradicate the virus. Several observations in primate models and in humans support the notion that cell-mediated immunity can control viral replication and slow disease progression. Thus, besides drugs, an immunotherapy that induces long-lasting HIV-specific T-cell responses could play a role in the treatment of HIV/AIDS. To induce such immune responses, DermaVir Patch has been developed. DermaVir consists of an HIV-1 antigenencoding plasmid DNA that is chemically formulated in a nanoparticle. DermaVir is administered under a patch after a skin preparation that supports the delivery of the nanoparticle to Langerhans cells (LC). Epidermal LC trap and transport the nanomedicine to draining lymph nodes. While in transit, LC mature into dendritic cells (DC), which can efficiently present the DNA-encoded antigens to naive T-cells for the induction of cellular immunity. Pre-clinical studies and Phase I clinical testing of DermaVir in HIV-1-infected individuals have demonstrated the safety and tolerability of DermaVir Patch. To further modulate cellular immunity, molecular adjuvants might be added into the nanoparticle. DermaVir Patch represents a new nanomedicine platform for immunotherapy of HIV/AIDS. In this review, the antiviral activity of DermaVir-induced cellular immunity is discussed. Furthermore, the action of some cytokines currently being tested as adjuvants are highlighted and the adjuvant effect of cytokine plasmid DNA included in the DermaVir nanopartcile is reviewed.
Keywords: HIV-1, DermaVir, Topical vaccine administration, Dendritic cells, Cellular immunity, Cytokines, Molecular adjuvants
Current Medicinal Chemistry
Title: Nanochemistry-Based Immunotherapy for HIV-1
Volume: 14 Issue: 18
Author(s): F. Lori, S.A. Calarota and J. Lisziewicz
Affiliation:
Keywords: HIV-1, DermaVir, Topical vaccine administration, Dendritic cells, Cellular immunity, Cytokines, Molecular adjuvants
Abstract: Highly active antiretroviral treatment (HAART), i.e. the combination of three or more drugs against human immunodeficiency virus type 1 (HIV-1), has greatly improved the clinical outcome of HIV-1-infected individuals. However, HAART is unable to reconstitute HIV-specific immunity and eradicate the virus. Several observations in primate models and in humans support the notion that cell-mediated immunity can control viral replication and slow disease progression. Thus, besides drugs, an immunotherapy that induces long-lasting HIV-specific T-cell responses could play a role in the treatment of HIV/AIDS. To induce such immune responses, DermaVir Patch has been developed. DermaVir consists of an HIV-1 antigenencoding plasmid DNA that is chemically formulated in a nanoparticle. DermaVir is administered under a patch after a skin preparation that supports the delivery of the nanoparticle to Langerhans cells (LC). Epidermal LC trap and transport the nanomedicine to draining lymph nodes. While in transit, LC mature into dendritic cells (DC), which can efficiently present the DNA-encoded antigens to naive T-cells for the induction of cellular immunity. Pre-clinical studies and Phase I clinical testing of DermaVir in HIV-1-infected individuals have demonstrated the safety and tolerability of DermaVir Patch. To further modulate cellular immunity, molecular adjuvants might be added into the nanoparticle. DermaVir Patch represents a new nanomedicine platform for immunotherapy of HIV/AIDS. In this review, the antiviral activity of DermaVir-induced cellular immunity is discussed. Furthermore, the action of some cytokines currently being tested as adjuvants are highlighted and the adjuvant effect of cytokine plasmid DNA included in the DermaVir nanopartcile is reviewed.
Export Options
About this article
Cite this article as:
F. Lori , S.A. Calarota and J. Lisziewicz , Nanochemistry-Based Immunotherapy for HIV-1, Current Medicinal Chemistry 2007; 14 (18) . https://dx.doi.org/10.2174/092986707781368513
DOI https://dx.doi.org/10.2174/092986707781368513 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Haptoglobin Phenotype May Alter Endothelial Progenitor Cell Cluster Formation in Cerebral Small Vessel Disease
Current Neurovascular Research Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas
Current Angiogenesis (Discontinued) Targeting Microglial Polarization to Improve TBI Outcomes
CNS & Neurological Disorders - Drug Targets A Review of Clinical Trials of Belimumab in the Management of Systemic Lupus Erythematosus
Current Pharmaceutical Design Immune Cell Entry to Central Nervous System - Current Understanding and Prospective Therapeutic Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets What do we know about Toll-Like Receptors Involvement in Gout Arthritis?
Endocrine, Metabolic & Immune Disorders - Drug Targets Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update
Current Neuropharmacology A Chronic Inflammatory Inductive Condition in the Nursing Profession: A Scoping Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Inflammation and Immune Regulation as Potential Drug Targets in Antidepressant Treatment
Current Neuropharmacology New Insights into Chemistry and Anti-Infective Potential of Triazole Scaffold
Current Medicinal Chemistry Pharmacotherapies for Glaucoma
Current Molecular Medicine Targeted Delivery of Therapeutics to Urological Cancer Stem Cells
Current Pharmaceutical Design Development of Dry Powder Inhalers
Recent Patents on Drug Delivery & Formulation Inhibitory Role of Resveratrol in the Development of Profibrogenesis and Fibrosis Mechanisms
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Patent Selections
Recent Patents on Biomarkers Total Syntheses and Anti-inflammatory Evaluations of Karanjin and its Natural Analogues
Letters in Organic Chemistry Proteomics in Acute Myelogenous Leukaemia (AML): Methodological Strategies and Identification of Protein Targets for Novel Antileukaemic Therapy
Current Drug Targets Homogeneous Time Resolved Fluorescence Assay to Measure Histamine Release
Combinatorial Chemistry & High Throughput Screening Meloxicam Prevents Load-Induced Cardiac Hypertrophy in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Update on the Medical Treatment of Allergic Rhinitis
Inflammation & Allergy - Drug Targets (Discontinued)